This content is from: Premium Icahn’s Private Hedge Fund Lost Money in 2022 The activist investor also sharply slashed his stake in HERC Holdings in February. By Stephen Taub February 28, 2023
This content is from: Premium Biopharma Funds Stumble in February But several funds may already be racking up big gains in March. By Stephen Taub March 16, 2023
This content is from: Premium Seligman’s Wick Predicted the Tech Rally The manager who enjoyed a profitable 2022 singles out seven companies with low valuations. By Stephen Taub March 17, 2023
This content is from: Portfolio A New, Esoteric Royalty Market Is Poised to Take Off About a dozen companies planning to go public via an IPO or SPAC are planning on using tax receivable agreements, which are now a $30 billion market, according to Parallaxes Capital. By Michael Thrasher February 15, 2023
This content is from: Premium The Soros Family Office Takes Several New Positions Soros Fund Management both added and unloaded at the end of 2022. By Stephen Taub February 14, 2023
This content is from: Premium Casdin Leads a Biopharma Surge Several funds that lost large amounts last year rebounded nicely in the first month of 2023. By Stephen Taub February 21, 2023
